Trial Profile

IMpAct of CardiolRxTM oVer 6 Months Following IL-1 Blocker Cessation in pERICarditis Patients - MAVERIC A Randomized, Double-blind, Placebo-controlled Trial

Status: Recruiting

Phase of Trial: Phase II/III

Latest Information Update: 08 Jul 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cannabidiol (Primary)
Indications Pericarditis
Focus Registrational; Therapeutic Use
Acronyms MAVERIC
Sponsors Cardiol Therapeutics

Most Recent Events

30 Apr 2025 Status changed from not yet recruiting to recruiting.
13 Feb 2025 Planned End Date changed from 15 Jul 2026 to 28 Sep 2026.
13 Feb 2025 Planned primary completion date changed from 15 Jun 2026 to 28 Aug 2026.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com